$18.46 -0.12 (-0.65%) Portola Pharmaceuticals Inc - NASDAQ

Dec. 6, 2016 | 11:05 AM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 18.46
Trade Time: Dec 06 11:05 AM Eastern Daylight Time
Change: -0.12 (-0.65%)
Prev Close: 18.58
Open: 18.69
Bid: 18.46
Ask: 18.48
  1. No results found.
  1. Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at #ASH2015

    Benzinga | Dec. 5, 2015 | 10:28AM EST
  2. Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients

    Benzinga | Oct. 13, 2015 | 07:04AM EST
  3. Portola Pharma Reports Will Present Data on Dual Kinase Inhibitor Cerdulatinib at ASCO

    Benzinga | May. 18, 2015 | 07:05AM EST
  4. Portola Reports Q4 EPS -$0.82 Vs Est -$0.90, Announce Positive Phase 3 ANNEXA-R Study

    Benzinga | Mar. 2, 2015 | 08:05AM EST
  5. What Investors Should Expect From Portola Pharmaceutical's Upcoming Data Readouts

    Benzinga | Jan. 9, 2015 | 12:43PM EST
  6. Friday's Morning Movers: Earnings Start To Trickle In

    Benzinga | Jan. 9, 2015 | 10:06AM EST
  7. Portola Pharmaceuticals Announces Commercial Supply Agreement For Andexanet Alfa With Lonza

    Benzinga | Oct. 16, 2014 | 15:08PM EST
  8. Portola Pharmaceuticals Announces Proposed Offering of Common Stock For Gross Proceeds Of $160M

    Benzinga | Oct. 1, 2014 | 15:26PM EST
  9. Midday Gainers From October 1 - Angie's List Inc, Tekmira Pharmaceuticals Corporation And More

    Benzinga | Oct. 1, 2014 | 11:52AM EST
  10. Morning Market Movers

    Benzinga | Oct. 1, 2014 | 08:39AM EST
  11. Paulson Bets Again On Mallinckrodt

    GuruFocus | Aug. 7, 2014 | 10:02AM EST
  12. Top 4 Stocks In The Biotechnology Industry With The Highest EPS

    Benzinga | Jun. 25, 2014 | 03:54AM EST
  13. Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, and XARELTO(R)

    Benzinga | Feb. 3, 2014 | 08:02AM EST
  14. Portola Pharma Reports New Phase 2 Results Confirming Immediate, Dose-Dependent, Well-Tolerated Reversal of Anticoagulation Activity of XARELTO

    Benzinga | Dec. 9, 2013 | 11:04AM EST
  15. Portola Pharma Issues Results for First Phase 2 Trial Showing Extended Duration Infusion with PRT4445

    Benzinga | Oct. 14, 2013 | 16:06PM EST
Trading Center